Objective To investigate the differences in the use of hepatoprotective and enzyme-lowering drugs among liver disease patients before and after the implementation of the National Medical Insurance Drug List,as well as the impact on patients'out-of-pocket expenses,and to provide clinical and pharmacoeconomic insights for the dynamic adjustment of the drug list.Methods Clinical data of 4 432 patients before and after the adjustment were collected.The analysis included the calcula-tion of Drug Utilization Index(DUI),Defined Daily Doses(DDDs),and Drug Daily Costs(DDC),along with an examination of medical expenses data to assess differences before and after the adjustment.Results After the adjustment,the DDC of the main drugs significantly decreased,with the DDC of ornithine aspartate dropping from 244.32 yuan to 73.50 yuan,and the DDC of hepatocyte promoting hormone reducing to as low as 12.20 yuan.The average length of hospital stay for the main disease cate-gories decreased by 0.08-14.89 days,the average cost per hospitalization dropped by 884.04-31 298.99 yuan,and the cost of liver-protecting and enzyme-lowering drugs decreased by 52.03-687.84 yuan,all with no statistical significance(P＞0.05).The average out-of-pocket cost and the proportion of out-of-pocket visits for liver-protecting and enzyme-lowering drugs increased,both with statistical significance(P＜0.05),among the average out-of-pocket cost for patients using magnesium isoglycyrrhizinate increased from 0.00 yuan to 566.05 yuan.The average reimbursement ratio decreased,with statistical significance(P＜0.05),among which the average reimbursement ratio for patients using ornithine aspartate decreased by 6.89 percentage points.Conclu-sion The adjustment of the National Medical Insurance Drug List has led to a narrower coverage scope for hepatoprotective and enzyme-lowering drugs,resulting in higher out-of-pocket expenses for liver disease patients.It is recommended that the restric-tions on these drugs be adjusted according to their indications to enhance the fairness of the insurance drug list and improve the accessibility of liver disease treatments.
health insurance drug listliver protection and enzyme loweringdrug for liver diseasepharmacoeconom-icsfairness
维普
万方数据
